GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
62.96 USD   +0.82%
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
08/09Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups
RE
08/09Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences Says Phase 3 Trial of Hepatitis Drug Meets Primary Endpoint

06/23/2022 | 09:32am EDT


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
08/09Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups
RE
08/09Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobili..
BU
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/08GILEAD SCIENCES, INC. : Report
CO
08/08GILEAD SCIENCES, INC. : SEC Filing 10Q-2
CO
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
08/04Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million
MT
08/04Gilead Sciences to Acquire MiroBio
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 181 M - -
Net income 2022 3 912 M - -
Net Debt 2022 16 314 M - -
P/E ratio 2022 19,9x
Yield 2022 4,63%
Capitalization 78 912 M 78 912 M -
EV / Sales 2022 3,78x
EV / Sales 2023 3,76x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 62,96 $
Average target price 70,35 $
Spread / Average Target 11,7%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968
GENMAB A/S0.23%23 726